Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Szilvia Lovas, Gergely Varga, Péter Farkas, Tamás Masszi, Nikolett Wohner, Ágnes Bereczki, Nóra Adamkovich, Zita Borbényi, Árpád Szomor, Hussain Alizadeh, Erika Szaleczky, Krisztina Wolf, Tamás Schneider, Márk Plander, Tamás Szendrei, Ottó Csacsovszki, Zoltán Csukly, Péter Rajnics, Miklós Egyed, Zsolt NagyLászló Rejtő, Árpád Illés, Gábor Mikala, László Váróczy

Research output: Article

2 Citations (Scopus)

Abstract

Daratumumab is a human anti-CD38 monoclonal antibody used in the treatment of refractory and relapsed multiple myeloma. We investigated the efficacy and safety of daratumumab therapy in a real-world setting. Ninety-nine Hungarian patients were included; 48 received monotherapy, while lenalidomide and bortezomib combinations were administered in 29 and 19 cases, respectively. Overall response rate was assessable in 88 patients, with 12 complete, 10 very good partial, 34 partial, and seven minor responses. At a median duration of follow-up of 18.6 months, median progression-free survival (PFS) among all patients was 17.0 months. These values were inferior in the bortezomib combination and monotherapy groups. Patients with early-stage disease (ISS1) had better survival results than those with stage 2 or 3 myeloma (p = 0.009). Heavily pretreated patients had inferior PFS compared to those with 1–3 therapies (p = 0.035). Patients with impaired renal function had PFS results comparable with those having no kidney involvement. There were 10 fatal infections, and the most frequent adverse events were mild infusion-associated reactions and hematologic toxicities. Our results confirm that daratumumab is an effective treatment option for relapsed/refractory MM with an acceptable safety profile in patients with normal and impaired renal function.

Original languageEnglish
Pages (from-to)559-565
Number of pages7
JournalInternational Journal of Hematology
Volume110
Issue number5
DOIs
Publication statusPublished - nov. 1 2019

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients'. Together they form a unique fingerprint.

  • Cite this

    Lovas, S., Varga, G., Farkas, P., Masszi, T., Wohner, N., Bereczki, Á., Adamkovich, N., Borbényi, Z., Szomor, Á., Alizadeh, H., Szaleczky, E., Wolf, K., Schneider, T., Plander, M., Szendrei, T., Csacsovszki, O., Csukly, Z., Rajnics, P., Egyed, M., ... Váróczy, L. (2019). Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients. International Journal of Hematology, 110(5), 559-565. https://doi.org/10.1007/s12185-019-02715-w